Incyte pancreatic cancer drug improves survival in mid-stage trial

(Reuters) – Incyte Corp reported an improved survival rate in patients most likely to benefit from its experimental pancreatic cancer treatment, Jakafi, sending the company’s shares up 30 percent to its highest in almost 13 years. Analysts said the data from a mid-stage trial suggested that the drug, already approved in the U.S. to treat a form of blood cancer, can work in a late-stage pancreatic cancer study, as well as on other cancerous tumors. …